Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) FCF Margin (2017 - 2025)

Protagonist Therapeutics' FCF Margin history spans 9 years, with the latest figure at 518.45% for Q4 2025.

  • For Q4 2025, FCF Margin fell 50137.0% year-over-year to 518.45%; the TTM value through Dec 2025 reached 121.87%, up 7894.0%, while the annual FY2025 figure was 121.87%, 7949.0% up from the prior year.
  • FCF Margin for Q4 2025 was 518.45% at Protagonist Therapeutics, down from 12.46% in the prior quarter.
  • Across five years, FCF Margin topped out at 6445.62% in Q2 2024 and bottomed at 1625.49% in Q2 2022.
  • The 5-year median for FCF Margin is 209.07% (2021), against an average of 87.83%.
  • The largest annual shift saw FCF Margin tumbled -1553064bps in 2021 before it soared 60001bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 325.12% in 2021, then surged by 91bps to 28.18% in 2022, then surged by 680bps to 163.54% in 2023, then plummeted by -110bps to 17.08% in 2024, then tumbled by -2936bps to 518.45% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's FCF Margin are 518.45% (Q4 2025), 12.46% (Q3 2025), and 542.82% (Q2 2025).